Please assess the completion status of the following clinical trial:

Trial Title: Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who are treated with TREDAPTIVE tablet within current local label for the first time~* Participants with primary hypercholesterolemia or mixed dyslipidemia~* Participants who are treated with TREDAPTIVE for more than or equal to 24 weeks will be included in long-term surveillance~* Special participants with known hepatic disorder or renal disorder, participants 65 years old or older, participants younger than 19 years old, and pregnant woman will be evaluated if collected.~Exclusion Criteria:~* Participant who is treated with TREDAPTIVE tablet before contract and out of enrollment period~* Participant who has a contraindication to TREDAPTIVE tablet according to the current local label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: None): Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)

Based on this trial design, predict the completion outcome and termination type (if applicable).